vMap™’s Role in Optimizing Non-Invasive Radio-Ablation Therapy presented at ACC.21 and THRS 2021

June 10, 2021 |

2 min read

Vektor Medical, Inc. announced that a dual-center study reports that vMap™, as part of a new, non-invasive workflow, improved efficiency and precision for radio-ablation therapy in the six studied patients.

A dual-center study from UCSD Health and Mills-Peninsula Sutter Health concluded that a simplified, non-invasive radio-ablation workflow, involving vMap™, was Feasible, Efficient, and Precise

CARLSBAD, Calif.--(BUSINESS WIRE)-- Vektor Medical, Inc. announced that a dual-center study reports that vMap™, as part of a new, non-invasive workflow, improved efficiency and precision for radio-ablation therapy in the six studied patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005300/en/

The study found vMap™ was capable of localizing ventricular tachycardia exit sites for all study patients. (Graphic: Business Wire)

The study found vMap™ was capable of localizing ventricular tachycardia exit sites for all study patients - in contrast to invasive mapping, which was only available to half of the patients in the study due to pre-existing conditions, such as intracardiac thrombi, intracardiac mass, and frailty. And, for the patients who were eligible for invasive mapping, vMap™ was able to identify the correct anatomic segment in 100% of cases.

Conducted at University of California San Diego and Mills-Peninsula Sutter Health, the study also showed that after radio-ablation under the enhanced workflow, ICD shocks for patients receiving the therapy were also significantly reduced.

“We’re thrilled that this research shows vMap™ was able to support the effective treatment of patients who were unable to undergo traditional invasive ablation therapy, especially for those with VT for whom other therapeutic options have failed previously.” Rob Krummen, President and COO of Vektor Medical.

Presented by its lead author Dr. Gordon Ho at American College of Cardiology 2021 and the Taiwan Heart Rhythm Society 2021 (THRS), the research won first prize in the “Clinical - Ventricular Arrhythmias/Cardiac Implanted Electronic Device” category at THRS.

About Vektor Medical, Inc.: Vektor Medical has developed a patented, next generation technology designed for functionally mapping cardiac arrhythmias. Vektor Medical was founded in 2017 by a team of engineers, scientists, doctors and entrepreneurs with the shared belief that harnessing the power of computational modeling could vastly improve cardiac arrhythmia care. Vektor Medical is based in Carlsbad, CA. To learn more, visit https://www.vektormedical.com.

About vMap™: vMap™ is a proprietary, non-invasive arrhythmia mapping technology that analyzes the information contained in a patient’s standard ECG. The vMap™ technology has been designed to provide physicians with actionable information on arrhythmias in all four chambers of the heart using a rapid, non-invasive, and workflow-optimized process. These insights are designed to assist the evaluation, investigation, and treatment of the arrhythmia source. Vektor Medical is in the process of applying for FDA clearance for vMap™, which is not currently available for distribution.